Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
B
Bailu Peng
Researcher
Also affiliated: The University of Texas MD Anderson Cancer Center (2002–2009); Changsha Medical University (1999); Yunnan Agricultural University (2009); Yunnan Animal Science and Veterinary Institute (2009); Hunan Cancer Hospital (1999); Winthrop Rockefeller Foundation (2021–2023); Southern Medical University (2013); The University of Texas Health Science Center at Houston (2004)
Faculty Researcher
17 h-index
29 pubs
2,481 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Bailu Peng's research focuses on understanding the molecular mechanisms underlying multiple myeloma, a type of cancer affecting plasma cells. Peng's work investigates how specific genes and cellular pathways influence disease progression and immune response in multiple myeloma patients. Recent publications explore the role of CST6 in suppressing osteolytic bone disease, the potential of bispecific CAR-T cells targeting BCMA and CD24 for treatment, and how high NEK2 expression in myeloid progenitors suppresses T cell immunity. Additionally, research examines how NEK2 inhibition can enhance the efficacy of PD-1/PD-L1 blockade therapies in multiple myeloma. Peng collaborates with Fenghuang Zhan, Guido Tricot, John D. Shaughnessy, and Fumou Sun at the University of Arkansas for Medical Sciences, with whom they have co-authored multiple publications. Peng has an h-index of 17, with 29 total publications and over 2,400 citations.
Metrics
- h-index: 17
- Publications: 29
- Citations: 2,481
Selected Publications
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)
-
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021)
-
Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma (2021)
-
CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction (2020)
Collaboration Network
Top Collaborators
Fumou Sun
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Yan Cheng
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Hongwei Xu
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Frits van Rhee
Winthrop Rockefeller Foundation
4 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Siegfried Janz
Medical College of Wisconsin (US)
3 shared publications
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Guido Tricot
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
John D. Shaughnessy
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Dongzheng Gai
Winthrop Rockefeller Foundation
3 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Fenghuang Zhan
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Huojun Cao
University of Iowa (US)
2 shared publications
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Jin‐Ran Chen
Arkansas Children's Nutrition Center
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Cody Ashby
University of Arkansas for Medical Sciences
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Carolina Schinke
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
2 shared publications
In database
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Similar Researchers
Based on overlapping research topics
Carolina Schinke
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Megan Darrington
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Maurizio Zangari
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Behjatolah Monzavi-Karbassi
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Receptor Mechanisms and Signaling
Ravi Sun BE
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Receptor Mechanisms and Signaling